Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT3789

Small molecule · Degrader of SMARCA2 · developed by Prelude Therapeutics

Phase 2 Most advanced trial (none active)
PRLD Developer
1 Registered trials

What is PRT3789?

PRT3789 is a targeted protein degrader that links a SMARCA2-binding moiety to an E3 ubiquitin ligase-binding moiety, inducing proteasome-mediated degradation of SMARCA2 (BRM). It is being studied in SMARCA4-deleted cancers, which depend on SMARCA2 for survival, including solid tumors, esophageal cancer and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
SMARCA2, SMARCA4 (biomarker)
Mechanism
Degrader of SMARCA2
Pathways
SWI/SNF chromatin remodeling, transcriptional regulation, oncogenic pathway downregulation
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06682806 Phase 2 Advanced Solid Tumor Terminated PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorEsophageal CancerMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutation

Other drugs acting on SMARCA2

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT3789

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.